4910627 said its fourth-quarter normalized net income was 31 cents per share, compared with the S&P Capital IQ consensus estimate of 35 cents per share.

EPS decreased 10.3% year over year from 35 cents.

Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was $3.7 million, a decline of 12.3% from $4.2 million in the prior-year period.

The normalized profit margin declined to 6.1% from 6.8% in the year-earlier period.

Total revenue declined on an annual basis to $61.3 million from $62.3 million, and total operating expenses rose from the prior-year period to $55.8 million from $53.5 million.

Reported net income rose 47.3% on an annual basis to $3.9 million, or 33 cents per share, from $2.7 million, or 21 cents per share.

For the year, the company's normalized net income totaled $1.64 per share, compared with the S&P Capital IQ consensus normalized EPS estimate of $1.71.

EPS declined from $1.68 in the prior year.

Normalized net income was $19.8 million, a decline of 7.4% from $21.4 million in the prior year.

Full-year total revenue declined on an annual basis to $272.8 million from $285.3 million, and total operating expenses decreased on an annual basis to $242.0 million from $250.4 million.

he company said reported net income decreased 7.3% on an annual basis to $19.6 million, or $1.62 per share, in the full year, from $21.1 million, or $1.65 per share.Medifast Inc.

4910627 said its fourth-quarter normalized net income was 31 cents per share, compared with the S&P Capital IQ consensus estimate of 35 cents per share.